Refine
Has Fulltext
- yes (16)
Is part of the Bibliography
- yes (16)
Year of publication
Document Type
- Journal article (12)
- Doctoral Thesis (4)
Keywords
- neurodegeneration (16) (remove)
Institute
- Neurologische Klinik und Poliklinik (7)
- Institut für Anatomie und Zellbiologie (3)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (3)
- Theodor-Boveri-Institut für Biowissenschaften (3)
- Institut für Virologie und Immunbiologie (2)
- Frauenklinik und Poliklinik (1)
- Institut für Humangenetik (1)
- Institut für Klinische Neurobiologie (1)
- Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (1)
- Lehrstuhl für Molekulare Psychiatrie (1)
Neuroinflammation has been suggested as a pathogenetic mechanism contributing to Parkinson’s disease (PD). However, anti-inflammatory treatment strategies have not yet been established as a therapeutic option for PD patients. We have used a human α-synuclein mouse model of progressive PD to examine the anti-inflammatory and neuroprotective effects of inflammasome inhibition on dopaminergic (DA) neurons in the substantia nigra (SN). As the NLRP3 (NOD-, LRR- and pyrin domain-containing 3)-inflammasome is a core interface for both adaptive and innate inflammation and is also highly druggable, we investigated the implications of its inhibition. Repeat administration of MCC950, an inhibitor of NLRP3, in a PD model with ongoing pathology reduced CD4\(^+\) and CD8\(^+\) T cell infiltration into the SN. Furthermore, the anti-inflammasome treatment mitigated microglial activation and modified the aggregation of α-synuclein protein in DA neurons. MCC950-treated mice showed significantly less neurodegeneration of DA neurons and a reduction in PD-related motor behavior. In summary, early inflammasome inhibition can reduce neuroinflammation and prevent DA cell death in an α-synuclein mouse model for progressive PD.